UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

A 'loving' mum killed her disabled son and took her own life after finding out she had days to live. Shirley Nunn ...

Lung cancer cases are rising among non-smokers. Learn about the causes, symptoms, and prevention strategies from a medical expert. Protect yourself and your loved ones with this vital information.

As monotherapy for treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations, after failure of platinum-based therapy.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

On 24 October, just two days after being discharged from hospital, a distress call from the woman's sister prompted Cleveland ...

Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...

Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...